Business
Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal
San Diego, California--(Newsfile Corp. - April 3, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a
About this update from Skye Bioscience, Inc.
[{"type":"text","content":"San Diego, California--(Newsfile Corp. - April 3, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) (\"Skye\" or the \"Company\"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that in a preclinical study using one of its experimental cannabinoid-derivative molecules, cannabidiol monovalinate hemisuccinate (\"CBD-Val-HS\"), called SBI-200, researchers observed significantly decreased pain responses in relevant animal pain models.\nIn contrast to cannabidiol (\"CBD\"), treatment of mice with SBI-200 resulted in significant analgesic effects compared to saline placebo in two different animal pain models. Interestingly, in a hot plate model, SBI-200 yielded an anti-pain effect equivalent to an analgesic dose (3.0 mg/kg) of oxycodone. Additionally, in a second model that emulates acute visceral pain, SBI-200, although less effective than oxycodone, was additive across both sub-analgesic and analgesic doses of oxycodone, suggesting Skye's novel molecule may address pain via an alternate mechanism than opiate-based pain modifiers.\n\"This early-stage research shows that our novel derivative of CBD provided a positive pain-reducing effect alone as well as in combination with oxycodone. While oxycodone is considered the gold standard analgesic, particularly for acute pain, given its addictive nature and other side effects, a cannabinoid derivative such as SBI-200 may be a potential alternative or complementary pain modifier,\" said Punit Dhillon, Chief Executive Officer of Skye.\n\"Skye has significantly expanded its experimental work focused on engaging cannabinoid receptors pertinent to a myriad of important diseases and conditions. This study highlights another therapeutic area that the endocannabinoid system may positively modulate. Beyond systemic pain management, these data are also relevant to ophthalmologic pathologies that often require management of both neuropathic and nociceptive-based pain, which aligns with and further supports the advancement of Skye's R&D pipeline.\"\nThis research was conducted by researchers at the University of Mississippi, which licensed the development and commercialization rights to SBI-200. The results of this study were published in the scientific journal Cannabis and Cannabinoid Research in a paper titled, \"Differential Effects of Canna...